LivaNova PLC $LIVN Shares Purchased by Legal & General Group Plc

Legal & General Group Plc raised its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 69.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 145,689 shares of the company’s stock after purchasing an additional 59,477 shares during the period. Legal & General Group Plc owned 0.27% of LivaNova worth $8,964,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hantz Financial Services Inc. increased its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the last quarter. State of Wyoming acquired a new position in LivaNova during the second quarter worth approximately $31,000. EverSource Wealth Advisors LLC increased its position in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the last quarter. Quarry LP purchased a new stake in LivaNova during the third quarter worth approximately $36,000. Finally, UMB Bank n.a. grew its stake in LivaNova by 63.0% during the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after buying an additional 306 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Trading Up 3.4%

LivaNova stock opened at $73.72 on Friday. The firm’s 50-day moving average is $67.40 and its 200-day moving average is $64.88. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $75.82. The company has a market cap of $4.05 billion, a P/E ratio of 37.81 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the firm posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts expect that LivaNova PLC will post 3.72 earnings per share for the current year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.35% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LIVN has been the subject of several research reports. Mizuho boosted their price objective on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Barclays boosted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Robert W. Baird decreased their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $79.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.